Balovaptan
- Generic Name
- Balovaptan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClN5O
- CAS Number
- 1228088-30-9
- Unique Ingredient Identifier
- RAX5D5AGV6
- Background
Balovaptan is under investigation in clinical trial NCT01793441 (A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)).
- Associated Conditions
- -
- Associated Therapies
- -
Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT05401565
- Locations
- 🇺🇸
CITrials, Inc., Bellflower, California, United States
🇺🇸ASCLEPES Research Centers, Panorama City, California, United States
🇺🇸Clinical Innovations, Inc, Santa Ana, California, United States
Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05399550
- Locations
- 🇺🇸
CPMC Comprehensive Stroke Care Center, San Francisco, California, United States
A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT04156646
- Locations
- 🇺🇸
PRA International Clinical Pharmacology Center (EDS US Clinic), Lenexa, Kansas, United States
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Balovaptan in Children With Autism Spectrum Disorder
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT04049578
- Locations
- 🇺🇸
Red Oak Psychiatry Associates, PA, Houston, Texas, United States
🇺🇸Richmond Behavioral Associates, Staten Island, New York, United States
🇺🇸University Hospitals Cleveland Medical Center; Division of Child and Adolescent Psychiatry, Cleveland, Ohio, United States
The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03912350
A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 16
- Registration Number
- NCT03586726
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Study to Investigate the Effect of Itraconazole on the PK of Multiple Doses of Balovaptan in Healthy Volunteers
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2019-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT03579719
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands
A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 322
- Registration Number
- NCT03504917
- Locations
- 🇺🇸
Woodland Research Northwest, LLC, Rogers, Arkansas, United States
🇺🇸MCB Clinical Research Centers, Colorado Springs, Colorado, United States
🇺🇸Millennium Psychiatric Associates, LLC, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.